Seres Therapeutics (MCRB) Change in Cash (2014 - 2026)

Seres Therapeutics has reported Change in Cash for 13 years, with the latest figure at -$15.9 million in Q1 2026.

• Quarterly Change in Cash fell 156.79% year-over-year to -$15.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.0 million (up 44.3% YoY) and the FY2025 annual result came in at $15.0 million, up 115.49% from the prior year.
• Change in Cash fell to -$15.9 million in Q1 2026 per MCRB's latest filing, from -$1.9 million in the prior quarter.
• Over five years, Change in Cash peaked at $134.7 million in Q2 2023 and troughed at -$68.2 million in Q1 2023.
• A 5-year average of -$8.8 million and a median of -$16.5 million in 2024 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2023: Change in Cash plunged 455.46% in 2022, then surged 610.76% in 2023.
• Over 5 years, Change in Cash stood at -$42.4 million in 2022, then climbed by 1.0% to -$41.9 million in 2023, then increased by 11.23% to -$37.2 million in 2024, then jumped by 94.97% to -$1.9 million in 2025, then sank by 751.07% to -$15.9 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$15.9 million, -$1.9 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.